Table of Contents Author Guidelines Submit a Manuscript
Autoimmune Diseases
Volume 2015 (2015), Article ID 943490, 18 pages
http://dx.doi.org/10.1155/2015/943490
Review Article

Understanding and Managing Pregnancy in Patients with Lupus

1Department of Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
2Systemic Autoimmune Diseases Research Unit, Hospital General Regional No. 36-CIBIOR, Instituto Mexicano del Seguro Social, Puebla, Mexico
3Department of Immunology and Rheumatology, Medicine School, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
4Department of Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil

Received 1 April 2015; Accepted 31 May 2015

Academic Editor: Juan-Manuel Anaya

Copyright © 2015 Guilherme Ramires de Jesus et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Lateef and M. Petri, “Managing lupus patients during pregnancy,” Best Practice and Research: Clinical Rheumatology, vol. 27, no. 3, pp. 435–447, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. M. E. B. Clowse, “Lupus activity in pregnancy,” Rheumatic Disease Clinics of North America, vol. 33, no. 2, pp. 237–252, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Peart and M. E. B. Clowse, “Systemic lupus erythematosus and pregnancy outcomes: an update and review of the literature,” Current Opinion in Rheumatology, vol. 26, no. 2, pp. 118–123, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. C. A. Clark, K. A. Spitzer, and C. A. Laskin, “Decrease in pregnancy loss rates in patients with systemic lupus erythematosus over a 40-year period,” Journal of Rheumatology, vol. 32, no. 9, pp. 1709–1712, 2005. View at Google Scholar · View at Scopus
  5. É. Vinet, J. Labrecque, C. A. Pineau et al., “A population-based assessment of live births in women with systemic lupus erythematosus,” Annals of the Rheumatic Diseases, vol. 71, no. 4, pp. 557–559, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Andrade, M. L. Sanchez, G. S. Alarcón et al., “Adverse pregnancy outcomes in women with systemic lupus erythematosus from a multiethnic US cohort: LUMINA (LVI) [corrected],” Clinical and Experimental Rheumatology, vol. 26, no. 2, pp. 268–274, 2008. View at Google Scholar
  7. M. E. B. Clowse, L. S. Magder, F. Witter, and M. Petri, “The impact of increased lupus activity on obstetric outcomes,” Arthritis and Rheumatism, vol. 52, no. 2, pp. 514–521, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. M. D. Lockshin, “Pregnancy does not cause systemic lupus erythematosus to worsen,” Arthritis & Rheumatism, vol. 32, no. 6, pp. 665–670, 1989. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Ruiz-Irastorza, F. Lima, J. Alves et al., “Increased rate of lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancies,” British Journal of Rheumatology, vol. 35, no. 2, pp. 133–138, 1996. View at Publisher · View at Google Scholar · View at Scopus
  10. M. E. B. Clowse, L. S. Magder, F. Witter, and M. Petri, “Early risk factors for pregnancy loss in lupus,” Obstetrics and Gynecology, vol. 107, no. 2, pp. 293–299, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. K.-L. Wong, F.-Y. Chan, and C.-P. Lee, “Outcome of pregnancy in patients with systemic lupus erythematosus. A prospective study,” Archives of Internal Medicine, vol. 151, no. 2, pp. 269–273, 1991. View at Publisher · View at Google Scholar · View at Scopus
  12. A. W. Shand, C. S. Algert, L. March, and C. L. Roberts, “Second pregnancy outcomes for women with systemic lupus erythematosus,” Annals of the Rheumatic Diseases, vol. 72, no. 4, pp. 547–551, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. K. T. Jørgensen, B. V. Pedersen, N. M. Nielsen, S. Jacobsen, and M. Frisch, “Childbirths and risk of female predominant and other autoimmune diseases in a population-based Danish cohort,” Journal of Autoimmunity, vol. 38, no. 2-3, pp. J81–J87, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Ostensen and M. Clowse, “Pathogenesis of pregnancy complications in systemic lupus erythematosus,” Current Opinion in Rheumatology, vol. 25, no. 5, pp. 591–596, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Munoz-Suano, A. B. Hamilton, and A. G. Betz, “Gimme shelter: the immune system during pregnancy,” Immunological Reviews, vol. 241, no. 1, pp. 20–38, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. D. W. Bianchi, G. K. Zickwolf, G. J. Weil, S. Sylvester, and M. A. Demaria, “Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 2, pp. 705–708, 1996. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Vinet, A. E. Clarke, C. Gordon et al., “Decreased live births in women with systemic lupus erythematosus,” Arthritis Care and Research, vol. 63, no. 7, pp. 1068–1072, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Doria, A. Ghirardello, L. Iaccarino et al., “Pregnancy, cytokines, and disease activity in systemic lupus erythematosus,” Arthritis Care & Research, vol. 51, no. 6, pp. 989–995, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Østensen, F. Förger, and P. M. Villiger, “Cytokines and pregnancy in rheumatic disease,” Annals of the New York Academy of Sciences, vol. 1069, pp. 353–363, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Q. Crome, A. Y. Wang, and M. K. Levings, “Translational mini-review series on Th17 cells: function and regulation of human T helper 17 cells in health and disease,” Clinical & Experimental Immunology, vol. 159, no. 2, pp. 109–119, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. M. H. Nyirenda, L. Sanvito, P. J. Darlington et al., “TLR2 stimulation drives human naive and effector regulatory T cells into a Th17-like phenotype with reduced suppressive function,” The Journal of Immunology, vol. 187, no. 5, pp. 2278–2290, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. A. B. Pernis, “Th17 cells in rheumatoid arthritis and systemic lupus erythematosus,” Journal of Internal Medicine, vol. 265, no. 6, pp. 644–652, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. E. Bettelli, M. Oukka, and V. K. Kuchroo, “TH-17 cells in the circle of immunity and autoimmunity,” Nature Immunology, vol. 8, no. 4, pp. 345–350, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. V. Saini, S. Arora, A. Yadav, and J. Bhattacharjee, “Cytokines in recurrent pregnancy loss,” Clinica Chimica Acta, vol. 412, no. 9-10, pp. 702–708, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Doria, L. Iaccarino, P. Sarzi-Puttini et al., “Estrogens in pregnancy and systemic lupus erythematosus,” Annals of the New York Academy of Sciences, vol. 1069, pp. 247–256, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Cutolo, A. Sulli, S. Capellino et al., “Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity,” Lupus, vol. 13, no. 9, pp. 635–638, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Conti, D. Kempuraj, K. Kandere et al., “IL-10, an inflammatory/inhibitory cytokine, but not always,” Immunology Letters, vol. 86, no. 2, pp. 123–129, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. R. K. Chowdary Venigalla, T. Tretter, S. Krienke et al., “Reduced CD4+,CD25- T cell sensitivity to the suppressive function of CD4+,CD25high,CD127-/low regulatory T cells in patients with active systemic lupus erythematosus,” Arthritis & Rheumatism, vol. 58, no. 7, pp. 2120–2130, 2008. View at Publisher · View at Google Scholar
  29. C. Tower, I. Crocker, D. Chirico, P. Baker, and I. Bruce, “SLE and pregnancy: the potential role for regulatory T cells,” Nature Reviews Rheumatology, vol. 7, no. 2, pp. 124–128, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Björkander, K. Bremme, J.-O. Persson, R. F. van Vollenhoven, E. Sverremark-Ekström, and U. Holmlund, “Pregnancy-associated inflammatory markers are elevated in pregnant women with systemic lupus erythematosus,” Cytokine, vol. 59, no. 2, pp. 392–399, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Andersen, L. Munthe-Fog, P. Garred, and S. Jacobsen, “Serum levels of ficolin-3 (Hakata antigen) in patients with systemic lupus erythematosus,” Journal of Rheumatology, vol. 36, no. 4, pp. 757–759, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Halmos, J. Rigó, J. Szijártó, G. Füst, Z. Prohászka, and A. Molvarec, “Circulating ficolin-2 and ficolin-3 in normal pregnancy and pre-eclampsia,” Clinical & Experimental Immunology, vol. 169, no. 1, pp. 49–56, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. D. Andrade, M. Kim, L. P. Blanco et al., “Interferon-α and angiogenic dysregulation in pregnant lupus patients destined for preeclampsia,” Arthritis & Rheumatology, vol. 67, no. 4, pp. 977–987, 2015. View at Publisher · View at Google Scholar
  34. S. Minamiguchi, Y. Mikami, N. Nakajima et al., “Complement split product C4d deposition in placenta in systemic lupus erythematosus and pregnancy-induced hypertension,” Pathology International, vol. 63, no. 3, pp. 150–157, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. D. N. Burns, P. Nourjah, D. J. Wright et al., “Changes in immune activation markers during pregnancy and postpartum,” Journal of Reproductive Immunology, vol. 42, no. 2, pp. 147–165, 1999. View at Publisher · View at Google Scholar · View at Scopus
  36. L. Jara-Quezada, A. Graef, and C. Lavalle, “Prolactin and gonadal hormones during pregnancy in systemic lupus erythematosus,” Journal of Rheumatology, vol. 18, no. 3, pp. 349–353, 1991. View at Google Scholar · View at Scopus
  37. A. Leaños-Miranda, G. Cárdenas-Mondragón, A. Ulloa-Aguirre, I. Isordia-Salas, A. Parra, and J. Ramírez-Peredo, “Anti-prolactin autoantibodies in pregnant women with systemic lupus erythematosus: maternal and fetal outcome,” Lupus, vol. 16, no. 5, pp. 342–349, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Doria, A. Tincani, and M. Lockshin, “Challenges of lupus pregnancies,” Rheumatology, vol. 47, supplement 3, pp. iii9–iii12, 2008. View at Google Scholar · View at Scopus
  39. C.-S. Yee, M. Akil, M. Khamashta et al., “The BILAG2004-pregnancy index is reliable for assessment of disease activity in pregnant SLE patients,” Rheumatology, vol. 51, no. 10, pp. 1877–1880, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. G. Ruiz-Irastorza and M. A. Khamashta, “Lupus and pregnancy: integrating clues from the bench and bedside,” European Journal of Clinical Investigation, vol. 41, no. 6, pp. 672–678, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. E. Imbasciati, A. Tincani, G. Gregorini et al., “Pregnancy in women with pre-existing lupus nephritis: predictors of fetal and maternal outcome,” Nephrology Dialysis Transplantation, vol. 24, no. 2, pp. 519–525, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. M. E. B. Clowse, L. S. Magder, and M. Petri, “The clinical utility of measuring complement and anti-dsDNA antibodies during pregnancy in patients with systemic lupus erythematosus,” Journal of Rheumatology, vol. 38, no. 6, pp. 1012–1016, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. E. Borella, A. Lojacono, M. Gatto et al., “Predictors of maternal and fetal complications in SLE patients: a prospective study,” Immunologic Research, vol. 60, no. 2-3, pp. 170–176, 2014. View at Publisher · View at Google Scholar
  44. H. Yang, H. Liu, D. Xu et al., “Pregnancy-related systemic lupus erythematosus: clinical features, outcome and risk factors of disease flares—a case control study,” PLoS ONE, vol. 9, no. 8, Article ID e104375, 2014. View at Publisher · View at Google Scholar
  45. T. J. Stanhope, W. M. White, K. G. Moder, A. Smyth, and V. D. Garovic, “Obstetric nephrology: lupus and lupus nephritis in pregnancy,” Clinical Journal of the American Society of Nephrology, vol. 7, no. 12, pp. 2089–2099, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. S. M. Ramin, A. C. Vidaeff, E. R. Yeomans, and L. C. Gilstrap III, “Chronic renal disease in pregnancy,” Obstetrics & Gynecology, vol. 108, no. 6, pp. 1531–1539, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. E. M. Klumb, L. M. S. Barros, L. Romeiro, N. R. de Jesús, R. A. Levy, and E. M. N. Albuquerque, “The impact of nephritis on gestational results in women with systemic lupus erythematosus,” Revista Brasileira de Reumatologia, vol. 45, no. 3, pp. 107–113, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. K. Bramham, B. J. Hunt, S. Bewley et al., “Pregnancy outcomes in systemic lupus erythematosus with and without previous nephritis,” Journal of Rheumatology, vol. 38, no. 9, pp. 1906–1913, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. C. K. Li and D. A. Isenberg, “Systemic lupus erythematosus,” Medicine, vol. 34, no. 11, pp. 445–452, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Smyth, G. H. M. Oliveira, B. D. Lahr, K. R. Bailey, S. M. Norby, and V. D. Garovic, “A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 11, pp. 2060–2068, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. J. P. Buyon, “Updates on lupus and pregnancy,” Bulletin of the NYU Hospital for Joint Diseases, vol. 67, no. 3, pp. 271–275, 2009. View at Google Scholar · View at Scopus
  52. K. P. Conrad and J. M. Davison, “The renal circulation in normal pregnancy and preeclampsia: is there a place for relaxin?” The American Journal of Physiology—Renal Physiology, vol. 306, no. 10, pp. F1121–F1135, 2014. View at Publisher · View at Google Scholar · View at Scopus
  53. M. A. Saavedra, C. Cruz-Reyes, O. Vera-Lastra et al., “Impact of previous lupus nephritis on maternal and fetal outcomes during pregnancy,” Clinical Rheumatology, vol. 31, no. 5, pp. 813–819, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. R. Fischer-Betz, C. Specker, R. Brinks, M. Aringer, and M. Schneider, “Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine,” Rheumatology, vol. 52, no. 6, pp. 1070–1076, 2013. View at Publisher · View at Google Scholar · View at Scopus
  55. F. Z. Rahman, J. Rahman, S. A. Al-Suleiman, and M. S. Rahman, “Pregnancy outcome in lupus nephropathy,” Archives of Gynecology and Obstetrics, vol. 271, no. 3, pp. 222–226, 2005. View at Publisher · View at Google Scholar · View at Scopus
  56. E. Oviasu, J. Hicks, and J. S. Cameron, “The outcome of pregnancy in women with lupus nephritis,” Lupus, vol. 1, no. 1, pp. 19–25, 1991. View at Publisher · View at Google Scholar · View at Scopus
  57. G. Moroni, S. Quaglini, G. Banfi et al., “Pregnancy in lupus nephritis,” American Journal of Kidney Diseases, vol. 40, no. 4, pp. 713–720, 2002. View at Publisher · View at Google Scholar · View at Scopus
  58. M. E. Clowse, M. Jamison, E. Myers, and A. H. James, “A national study of the complications of lupus in pregnancy,” The American Journal of Obstetrics & Gynecology, vol. 199, no. 2, pp. 127.e1–127.e6, 2008. View at Publisher · View at Google Scholar
  59. E. M. Klumb, C. A. Silva, C. C. Lanna et al., “Consensus of the Brazilian Society of Rheumatology for the diagnosis, management and treatment of lupus nephritis,” Revista Brasileira de Reumatologia, vol. 55, no. 1, pp. 1–21, 2015. View at Publisher · View at Google Scholar
  60. T. K. Chen, A. C. Gelber, F. R. Witter, M. Petri, and D. M. Fine, “Renal biopsy in the management of lupus nephritis during pregnancy,” Lupus, vol. 24, no. 2, pp. 147–154, 2015. View at Publisher · View at Google Scholar
  61. R. J. Levine, S. E. Maynard, C. Qian et al., “Circulating angiogenic factors and the risk of preeclampsia,” The New England Journal of Medicine, vol. 350, no. 7, pp. 672–683, 2004. View at Publisher · View at Google Scholar · View at Scopus
  62. G. de Jesus, N. de Jesus, R. Levy, and E. Klumb, “The use of angiogenic and antiangiogenic factors in the differential diagnosis of pre-eclampsia, antiphospholipid syndrome nephropathy and lupus nephritis,” Lupus, vol. 23, no. 12, pp. 1299–1301, 2014. View at Publisher · View at Google Scholar
  63. G. R. de Jesus, C. S. Oliveira, F. C. Santos et al., “Angiogenic and antiangiogenic factors in patients with systemic lupus erythematosus,” Arthritis & Rheumatology, vol. 66, supplement, p. S1157, 2014. View at Google Scholar
  64. C. E. Kleinrouweler, M. M. J. Wiegerinck, C. Ris-Stalpers et al., “Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis,” BJOG, vol. 119, no. 7, pp. 778–787, 2012. View at Publisher · View at Google Scholar · View at Scopus
  65. C. Oakley and C. A. Warnes, Heart Disease in Pregnancy, Blackwell Publishing, Malden, Mass, USA, 2nd edition, 2007.
  66. M. Bonnin, F. J. Mercier, O. Sitbon et al., “Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases,” Anesthesiology, vol. 102, no. 6, pp. 1133–1137, 2005. View at Publisher · View at Google Scholar · View at Scopus
  67. P. Lin, E. Rhew, R. B. Ness et al., “Adverse pregnancy outcomes and subsequent risk of cardiovascular disease in women with systemic lupus erythematosus,” Lupus Science & Medicine, vol. 1, no. 1, Article ID e000024, 2014. View at Publisher · View at Google Scholar
  68. J. E. Salmon, C. Heuser, M. Triebwasser et al., “Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort,” PLoS Medicine, vol. 8, no. 3, Article ID e1001013, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Tincani, C. Bazzani, S. Zingarelli, and A. Lojacono, “Lupus and the antiphospholipid syndrome in pregnancy and obstetrics: clinical characteristics, diagnosis, pathogenesis, and treatment,” Seminars in Thrombosis and Hemostasis, vol. 34, no. 3, pp. 267–273, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. J. A. Gómez-Puerta, G. Espinosa, and R. Cervera, “Catastrophic antiphospholipid syndrome: diagnosis and management in pregnancy,” Clinics in Laboratory Medicine, vol. 33, no. 2, pp. 391–400, 2013. View at Publisher · View at Google Scholar · View at Scopus
  71. M. Østensen, L. Andreoli, A. Brucato et al., “State of the art: reproduction and pregnancy in rheumatic diseases,” Autoimmunity Reviews, vol. 14, no. 5, pp. 376–386, 2015. View at Publisher · View at Google Scholar
  72. J. Alijotas-Reig, R. Ferrer-Oliveras, A. Ruffatti et al., “The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): a survey of 247 consecutive cases,” Autoimmunity Reviews, vol. 14, no. 5, pp. 387–395, 2015. View at Publisher · View at Google Scholar
  73. S. Sciascia, G. Sanna, V. Murru, D. Roccatello, M. A. Khamashta, and M. L. Bertolaccini, “GAPSS: the global anti-phospholipid syndrome score,” Rheumatology, vol. 52, no. 8, Article ID ket388, pp. 1397–1403, 2013. View at Publisher · View at Google Scholar · View at Scopus
  74. C. A. Clark, K. A. Spitzer, J. N. Nadler, and C. A. Laskin, “Preterm deliveries in women with systemic lupus erythematosus,” Journal of Rheumatology, vol. 30, no. 10, pp. 2127–2132, 2003. View at Google Scholar · View at Scopus
  75. M. J. Johnson, M. Petri, F. R. Witter, and J. T. Repke, “Evaluation of preterm delivery in a systemic lupus erythematosus pregnancy clinic,” Obstetrics and Gynecology, vol. 86, no. 3, pp. 396–399, 1995. View at Publisher · View at Google Scholar · View at Scopus
  76. S. Y. Yuen, A. Krizova, J. M. Ouimet, and J. E. Pope, “Pregnancy outcome in systemic lupus erythematosus (SLE) is improving: Results from a case control study and literature review,” The Open Rheumatology Journal, vol. 2, no. 1, pp. 89–98, 2009. View at Publisher · View at Google Scholar
  77. M. S. Magid, C. Kaplan, L. R. Sammaritano, M. Peterson, M. L. Druzin, and M. D. Lockshin, “Placental pathology in systemic lupus erythematosus: a prospective study,” The American Journal of Obstetrics and Gynecology, vol. 179, no. 1, pp. 226–234, 1998. View at Publisher · View at Google Scholar · View at Scopus
  78. K. Lun Hon and A. K. C. Leung, “Neonatal lupus erythematosus,” Autoimmune Diseases, vol. 2012, Article ID 301274, 6 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  79. P. M. Izmirly, M. Y. Kim, C. Llanos et al., “Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine,” Annals of the Rheumatic Diseases, vol. 69, no. 10, pp. 1827–1830, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. P. M. Izmirly, C. Llanos, L. A. Lee, A. Askanase, M. Y. Kim, and J. P. Buyon, “Cutaneous manifestations of neonatal lupus and risk of subsequent congenital heart block,” Arthritis and Rheumatism, vol. 62, no. 4, pp. 1153–1157, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. D. M. Friedman, M. Y. Kim, J. A. Copel, C. Llanos, C. Davis, and J. P. Buyon, “Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and Dexamethasone Evaluation (PRIDE) study,” The American Journal of Cardiology, vol. 103, no. 8, pp. 1102–1106, 2009. View at Publisher · View at Google Scholar · View at Scopus
  82. A. J. J. T. Rein, D. Mevorach, Z. Perles et al., “Early diagnosis and treatment of atrioventricular block in the fetus exposed to maternal anti-SSA/Ro-SSB/La antibodies a prospective, observational, fetal kinetocardiogram-based study,” Circulation, vol. 119, no. 14, pp. 1867–1872, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. J. P. Buyon, R. M. Clancy, and D. M. Friedman, “Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside,” Nature Clinical Practice Rheumatology, vol. 5, no. 3, pp. 139–148, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. E. T. Jaeggi, J.-C. Fouron, E. D. Silverman, G. Ryan, J. Smallhorn, and L. K. Hornberger, “Transplacental fetal treatment improves the outcome of prenatally diagnosed complete atrioventricular block without structural heart disease,” Circulation, vol. 110, no. 12, pp. 1542–1548, 2004. View at Publisher · View at Google Scholar · View at Scopus
  85. P. M. Izmirly, N. Costedoat-Chalumeau, C. N. Pisoni et al., “Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/ro-antibody—associated cardiac manifestations of neonatal lupus,” Circulation, vol. 126, no. 1, pp. 76–82, 2012. View at Publisher · View at Google Scholar · View at Scopus
  86. R. D. Tunks, M. E. B. Clowse, S. G. Miller, L. R. Brancazio, and P. C. A. Barker, “Maternal autoantibody levels in congenital heart block and potential prophylaxis with antiinflammatory agents,” American Journal of Obstetrics & Gynecology, vol. 208, no. 1, pp. 64.e1–64.e7, 2013. View at Publisher · View at Google Scholar · View at Scopus
  87. D. M. Friedman, C. Llanos, P. M. Izmirly et al., “Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: results of a multicenter, prospective, open-label clinical trial,” Arthritis and Rheumatism, vol. 62, no. 4, pp. 1138–1146, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. C. N. Pisoni, A. Brucato, A. Ruffatti et al., “Failure of intravenous immunoglobulin to prevent congenital heart block: findings of a multicenter, prospective, observational study,” Arthritis and Rheumatism, vol. 62, no. 4, pp. 1147–1152, 2010. View at Publisher · View at Google Scholar · View at Scopus
  89. J. G. Routsias, N. C. Kyriakidis, D. M. Friedman et al., “Association of the idiotype: antiidiotype antibody ratio with the efficacy of intravenous immunoglobulin treatment for the prevention of recurrent autoimmune-associated congenital heart block,” Arthritis & Rheumatism, vol. 63, no. 9, pp. 2783–2789, 2011. View at Publisher · View at Google Scholar · View at Scopus
  90. M. Østensen, “Intravenous immunoglobulin does not prevent recurrence of congenital heart block in children of SSA/Ro-positive mothers,” Arthritis and Rheumatism, vol. 62, no. 4, pp. 911–914, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. H. Eliasson, S.-E. Sonesson, G. Sharland et al., “Isolated atrioventricular block in the fetus: a retrospective, multinational, multicenter study of 175 patients,” Circulation, vol. 124, no. 18, pp. 1919–1926, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. P. M. Izmirly, A. Saxena, M. Y. Kim et al., “Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus,” Circulation, vol. 124, no. 18, pp. 1927–1935, 2011. View at Publisher · View at Google Scholar · View at Scopus
  93. G. R. R. de Jesus, F. C. Dos Santos, C. S. Oliveira, W. Mendes-Silva, N. R. de Jesus, and R. A. Levy, “Management of obstetric antiphospholipid syndrome,” Current Rheumatology Reports, vol. 14, no. 1, pp. 79–86, 2012. View at Publisher · View at Google Scholar · View at Scopus
  94. R. Madazli, M. A. Yuksel, M. Oncul, M. Imamoglu, and H. Yilmaz, “Obstetric outcomes and prognostic factors of lupus pregnancies,” Archives of Gynecology and Obstetrics, vol. 289, no. 1, pp. 49–53, 2014. View at Publisher · View at Google Scholar · View at Scopus
  95. G. Pagani, R. Reggia, L. Andreoli et al., “The role of second trimester uterine artery Doppler in pregnancies with systemic lupus erythematosus,” Prenatal Diagnosis, vol. 35, no. 5, pp. 447–452, 2015. View at Publisher · View at Google Scholar
  96. D. Le Thi Huong, B. Wechsler, D. Vauthier-Brouzes et al., “The second trimester Doppler ultrasound examination is the best predictor of late pregnancy outcome in systemic lupus erythematosus and/or the antiphospholipid syndrome,” Rheumatology, vol. 45, no. 3, pp. 332–338, 2006. View at Publisher · View at Google Scholar · View at Scopus
  97. B. H. Hahn, M. A. McMahon, A. Wilkinson et al., “American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis,” Arthritis Care and Research, vol. 64, no. 6, pp. 797–808, 2012. View at Publisher · View at Google Scholar · View at Scopus
  98. G. K. Bertsias, M. Tektonidou, Z. Amoura et al., “Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis,” Annals of the Rheumatic Diseases, vol. 71, no. 11, pp. 1771–1782, 2012. View at Publisher · View at Google Scholar · View at Scopus
  99. R. A. Levy, V. S. Vilela, M. J. Cataldo et al., “Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study,” Lupus, vol. 10, no. 6, pp. 401–404, 2001. View at Publisher · View at Google Scholar · View at Scopus
  100. A. Makol, K. Wright, and S. Amin, “Rheumatoid arthritis and pregnancy: safety considerations in pharmacological management,” Drugs, vol. 71, no. 15, pp. 1973–1987, 2011. View at Publisher · View at Google Scholar · View at Scopus
  101. A. Osadchy, T. Ratnapalan, and G. Koren, “Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature,” Journal of Rheumatology, vol. 38, no. 12, pp. 2504–2508, 2011. View at Publisher · View at Google Scholar · View at Scopus
  102. V. Jain and C. Gordon, “Managing pregnancy in inflammatory rheumatological diseases,” Arthritis Research and Therapy, vol. 13, no. 1, article 206, 2011. View at Publisher · View at Google Scholar · View at Scopus
  103. R. M. Ward, B. A. Bates, W. E. Benitz et al., “The transfer of drugs and other chemicals into human milk,” Pediatrics, vol. 108, no. 3, pp. 776–789, 2001. View at Google Scholar · View at Scopus
  104. J. M. W. Hazes, P. G. Coulie, V. Geenen et al., “Rheumatoid arthritis and pregnancy: evolution of disease activity and pathophysiological considerations for drug use,” Rheumatology, vol. 50, no. 11, pp. 1955–1968, 2011. View at Publisher · View at Google Scholar · View at Scopus
  105. J. Yazdany, L. Trupin, R. Kaiser et al., “Contraceptive counseling and use among women with systemic lupus erythematosus: a gap in health care quality?” Arthritis Care and Research, vol. 63, no. 3, pp. 358–365, 2011. View at Publisher · View at Google Scholar · View at Scopus
  106. E. B. Schwarz and S. Manzi, “Risk of unintended pregnancy among women with systemic lupus erythematosus,” Arthritis Care & Research, vol. 59, no. 6, pp. 863–866, 2008. View at Publisher · View at Google Scholar · View at Scopus
  107. K. R. Culwell, K. M. Curtis, and M. del Carmen Cravioto, “Safety of contraceptive method use among women with systemic lupus erythematosus: a systematic review,” Obstetrics and Gynecology, vol. 114, no. 2, part 1, pp. 341–353, 2009. View at Publisher · View at Google Scholar · View at Scopus
  108. E. M. Stringer, C. Kaseba, J. Levy et al., “A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus,” The American Journal of Obstetrics and Gynecology, vol. 197, no. 2, pp. 144.e1–144.e8, 2007. View at Publisher · View at Google Scholar · View at Scopus
  109. M. Cutolo, S. Capellino, and R. H. Straub, “Oestrogens in rheumatic diseases: friend or foe?” Rheumatology, vol. 47, supplement 3, pp. iii2–iii5, 2008. View at Google Scholar · View at Scopus
  110. J. Sánchez-Guerrero, A. G. Uribe, L. Jiménez-Santana et al., “A trial of contraceptive methods in women with systemic lupus erythematosus,” The New England Journal of Medicine, vol. 353, no. 24, pp. 2539–2549, 2005. View at Publisher · View at Google Scholar · View at Scopus
  111. M. Petri, M. Y. Kim, K. C. Kalunian et al., “Combined oral contraceptives in women with systemic lupus erythematosus,” The New England Journal of Medicine, vol. 353, no. 24, pp. 2550–2558, 2005. View at Publisher · View at Google Scholar · View at Scopus
  112. N. Chabbert-Buffet, Z. Amoura, P.-Y. Scarabin et al., “Pregnane progestin contraception in systemic lupus erythematosus: a longitudinal study of 187 patients,” Contraception, vol. 83, no. 3, pp. 229–237, 2011. View at Publisher · View at Google Scholar · View at Scopus
  113. A. M. Kaunitz, R. Arias, and M. McClung, “Bone density recovery after depot medroxyprogesterone acetate injectable contraception use,” Contraception, vol. 77, no. 2, pp. 67–76, 2008. View at Publisher · View at Google Scholar · View at Scopus
  114. C. J. Hardy, B. P. Palmer, S. J. Morton, K. R. Muir, and R. J. Powell, “Pregnancy outcome and family size in systemic lupus erythematosus: a case-control study,” Rheumatology, vol. 38, no. 6, pp. 559–563, 1999. View at Publisher · View at Google Scholar · View at Scopus
  115. R. A. Hickman and C. Gordon, “Causes and management of infertility in systemic lupus erythematosus,” Rheumatology, vol. 50, no. 9, pp. 1551–1558, 2011. View at Publisher · View at Google Scholar · View at Scopus
  116. C. A. Silva, E. Bonfa, and M. Østensen, “Maintenance of fertility in patients with rheumatic diseases needing antiinflammatory and immunosuppressive drugs,” Arthritis Care & Research, vol. 62, no. 12, pp. 1682–1690, 2010. View at Publisher · View at Google Scholar · View at Scopus
  117. Z. Blumenfeld, O. Mischari, N. Schultz, N. Boulman, and A. Balbir-Gurman, “Gonadotropin releasing hormone agonists may minimize cyclophosphamide associated gonadotoxicity in SLE and autoimmune diseases,” Seminars in Arthritis and Rheumatism, vol. 41, no. 3, pp. 346–352, 2011. View at Publisher · View at Google Scholar · View at Scopus
  118. M. C. Micu, R. Micu, and M. Ostensen, “Luteinized unruptured follicle syndrome increased by inactive disease and selective cyclooxygenase 2 inhibitors in women with inflammatory arthropathies,” Arthritis Care and Research, vol. 63, no. 9, pp. 1334–1338, 2011. View at Publisher · View at Google Scholar · View at Scopus
  119. N. Guballa, L. Sammaritano, S. Schwartzman, J. Buyon, and M. D. Lockshin, “Ovulation induction and in vitro fertilization in systemic lupus erythematosus and antiphospholipid syndrome,” Arthritis & Rheumatism, vol. 43, no. 3, pp. 550–556, 2000. View at Publisher · View at Google Scholar · View at Scopus
  120. L. C. Udoff and D. W. Branch, “Management of patients with antiphospholipid antibodies undergoing in vitro fertilization,” Journal of Autoimmunity, vol. 15, no. 2, pp. 209–211, 2000. View at Publisher · View at Google Scholar · View at Scopus
  121. A. Levine and M. Lockshin, “Assisted reproductive technology in SLE and APS,” Lupus, vol. 23, no. 12, pp. 1239–1241, 2014. View at Publisher · View at Google Scholar
  122. K. L. Buckingham and L. W. Chamley, “A critical assessment of the role of antiphospholipid antibodies in infertility,” Journal of Reproductive Immunology, vol. 80, no. 1-2, pp. 132–145, 2009. View at Publisher · View at Google Scholar · View at Scopus
  123. C. Coughlan, X. Yuan, T. Nafee, J. Yan, N. Mariee, and T. Li, “The clinical characteristics of women with recurrent implantation failure,” Journal of Obstetrics and Gynaecology, vol. 33, no. 5, pp. 494–498, 2013. View at Publisher · View at Google Scholar · View at Scopus
  124. A. Steinvil, R. Raz, S. Berliner et al., “Association of common thrombophilias and antiphospholipid antibodies with success rate of in vitro fertilisation,” Thrombosis and Haemostasis, vol. 108, no. 6, pp. 1192–1197, 2012. View at Publisher · View at Google Scholar · View at Scopus
  125. C. Chighizola and G. de Jesus, “Antiphospholipid antibodies and infertility,” Lupus, vol. 23, no. 12, pp. 1232–1238, 2014. View at Publisher · View at Google Scholar
  126. Practice Committee of American Society for Reproductive Medicine, “Anti-phospholipid antibodies do not affect IVF success,” Fertility and Sterility, vol. 90, no. 5, supplement, pp. S172–S173, 2008. View at Publisher · View at Google Scholar